Temporal arteritis

References cited
Article section 14 of 15.  Previous  Next

By James Goodwin MD

Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994;120:987-92.

Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014;93(5):194-201.

Allison M, Gallagher P. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis 1984;43:416-7.

Atluri P, Woo YJ. High-risk repair of ascending aortic aneurysm due to giant cell aortitis. Asian Cardiovasc Thorac Ann 2007;15(3):252-4.

Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 1994;37:1007-12.

Barber HS. Myalgic syndrome with constitutional effects. Polymyalgia rheumatica. Ann Rheum Dis 1957;16:230-7.

Bas-Lando M, Breuer GS, Berkun Y, Mates M, Sonnenblick M, Nesher G. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol 2007;25(1 Suppl 44):S15-7.

Bley TA, Wieben O, Uhl M, et al. Integrated head-thoracic vascular MRI at 3T: assessment of cranial, cervical and thoracic involvement of giant cell arteritis. MAGMA 2005;18:193-200.

Blockmans D, Coudyzer W, Vanderschueren S, et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 2008;47(8):1179-84.

Bosley TM, Savino PJ, Sergott RC, Eagle RC, Sandy R, Gee W. Ocular plethysmography can help in the diagnosis of giant-cell arteritis. Arch Ophthalmol 1989;107:379-81.

Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999;42:311-7.

Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988;38:352-9.

Chakrabarty A, Franks AJ. Temporal artery biopsy: is there any value in examining biopsies at multiple levels? J Clin Pathol 2000;53(2):131-6.

Chakravarty K, Elgabani SH, Scott DG, Merry P. A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994;33:152-6.

Chakravarty K, Pountain G, Merry P, Byron M, Hazleman B, Scott DG. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1995;22:1694-7.

Chiu CS, Dryja TP, Lessell S. A "negative" temporal artery biopsy, positive for arteritis. Arch Ophthalmol 2004;122(7):1074-5.

Chmelewski WL, McKnight KM, Agudelo CA, Wise CM. Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients. Arch Intern Med 1992;152:1690-5.

Cid MC, Hernandez-Rodriguez J, Esteban MJ, Cebrian M, Gho YS, Font C. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002;106(13):1664-71.

Corcoran GM, Prayson RA, Herzog KM. The significance of perivascular inflammation in the absence of arteritis in temporal artery biopsy specimens. Am J Clin Pathol 2001;115(3):342-7.

Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol 2004;14(3):245-57.

Cox M, Gilks B. Healed or quiescent temporal arteritis versus senescent changes in temporal artery biopsy specimens. Pathology 2001;33(2):163-6.

Cullen JF. Occult temporal arteritis. Trans Ophthalmol Soc U K 1963;83:725-36.

Czihal M, Brendel T, Seibold C, Reincke M, Hoffmann U. Listen to the axillary artery: diagnosis of occult giant cell arteritis. J Clin Rheumatol 2011;17:214-5.

Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25(11):2140-5.

Danesh-Meyer HV, Savino PJ, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001;108(3):593-8.

de Heide LJ, Talsma MA. Giant-cell arteritis presenting as an orbital pseudotumor. Neth J Med 1999;55:196-8.

Delecoeuillerie D, Joly P, Cohen DE, Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis; a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;477:33-9.

Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121(7):906-15.

De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;451:36-8.

de Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S. Treatment of giant cell arteritis with cyclophosphamide pulses [letter]. J Intern Med 1992;232:373-5.

Dimitrijevic I, Malmsjo M, Andersson C, Rissler P, Edvinsson L. Increased angiotensin II type 1 receptor expression in temporal arteries from patients with giant cell arteritis. Ophthalmology 2009;116(5):990-6.

Duhaut P, Pinede L, Bornet H, et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Arterite a Cellules Geantes. Ann Rheum Dis 1999a;58:335-41.

Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes 1998;41:1960-5.

Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and polymyalgia rheumatica: are pregnancies a protective factor? A prospective, multicentre case-control study. GRACG (Groupe de Recherche sur l'Arterite a Cellules Geantes). Rheumatology (Oxford) 1999b;38:118-23.

Elliott PD, Baker HL, Brown AL. Superficial temporal artery arteriogram. Radiology 1972;102:635-8.

Espinosa G, Tassies D, Font J, et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum 2001;31(1):12-20.

Esteban MJ, Font C, Hernandez-Rodriguez J, et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum 2001;44(6):1387-95.

Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;122:502-7.

Fernandez-Lopez MJ, Wamen S, Karmali R, Peretz A, Gonzalez-Gay MA, Bentin J. Low back pain as presenting manifestation of giant cell arteritis associated to abdominal aortitis. Clin Exp Rheumatol 2007;25(1 Suppl 44):S31-3.

Fledelius HC, Nissen KR. Giant cell arteritis and visual loss. A 3-year retrospective hospital investigation in a Danish county. Acta Ophthalmol (Copenh) 1992;70:801-5.

Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997;36(2):251-4.

Freddo T, Price M, Kase C, Goldstein MP. Myocardial infarction and coronary artery involvement in giant cell arteritis. Optom Vis Sci 1999;76:14-8.

Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999;42:1255-8.

Galor A, Lee MS. Slowly progressive vision loss in giant cell arteritis. Arch Ophthalmol 2006;124:416-8.

Garcia-Martinez A, Arguis P, Prieto-Gonzalez S, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis 2013. [Epub ahead of print]

Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008;59(3):422-30.

Ghaffar SA, Todd PM. Scalp necrosis secondary to giant-cell arteritis. Clin Exp Dermatol 2010;35(3):e40-1.

Gillanders LA. Temporal arteriography. Clin Radiol 1969;20:149-56.

Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004a;83(6):335-41.

Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001;60(4):367-71.

Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 2007;86(2):61-8.

Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004b;83(6):342-7.

Goodwin JA. Temporal arteritis. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Neurological manifestations of systemic diseases. Part II. New York: North-Holland, 1980:313-42.

Habib HM, Essa AA, Hassan AA. Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. Clin Rheumatol 2012;31(2):231-7.

Hall S, Persellin S, Lie JT, O'Brien PC, Kurland LT, Hunder GG. The therapeutic impact of temporal artery biopsy. Lancet 1983;212:17-20.

Hamano K, Gohra H, Katoh T, et al. An ascending aortic aneurysm caused by giant cell arteritis: report of a case. Surg Today 1999;29:957-9.

Hamilton CR, Shelley WM, Tumulty PA. Giant cell arteritis. Including temporal arteritis and polymyalgia rheumatica. Medicine (Baltimore) 1971;50:1-27.

Hamrin B. Polymyalgia arteritica with morphological changes in the large arteries. Acta Med Scand 1972;533(Suppl):4-164.

Hauenstein C, Reinhard M, Geiger J, et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology (Oxford) 2012 Jul 6. [Epub ahead of print].

Hautzel H, Sander O, Heinzel A, Schneider M, Muller HW. Assessment of Large-Vessel Involvement in Giant Cell Arteritis with 18F-FDG PET: Introducing an ROC-Analysis-Based Cutoff Ratio. J Nucl Med 2008;49(7):1107-1113.

Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. [Comments]. Am J Ophthalmol 1997;123(3):285-96.

Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998;125:509-20.

Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002;80(4):355-67.

Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1{beta}, TNF{alpha} and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004;43(3):294-301.

Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46(5):1309-18.

Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146(9):621-30.

Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Proc Mayo Clin 1932;7:700-1.

Hunder G, Bloch D, Michel B, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.

Hutchinson J. Disease of the arteries. Arch Surg 1889;1:323-9.

Hwang JM, Girkin CA, Perry JD, Lai JC, Miller NR, Hellmann DB. Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment. Am J Ophthalmol 1999;127:102-4.

Joelson E, Ruthrauff B, Ali F, Lindeman N, Sharp FR. Multifocal dural enhancement associated with temporal arteritis. Arch Neurol 2000;57:119-22.

Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 1999;42:2624-30.

Kadry Z, Mentha G, Cereda JM. Polymyalgia rheumatica as a manifestation of a large hepatic cavernous hemangioma. J Hepatol 2000;32(2):358-60.

Kimmelstiel P, Gilmour MT, Hodges HH. Degeneration of elastic fibers in granulomatous giant cell arteritis (temporal arteritis). Arch Pathol 1952;541:57-68.

Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Proc Mayo Clin 1976;51:504-10.

Klink T, Geiger J, Both M, et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 2014. [Epub ahead of print]

Kraft HE, Moller DE, Volker L, Schmidt WA. Color Doppler ultrasound of the temporal arteries-a new method for diagnosing temporal arteritis. Klin Monatsbl Augenheilkd 1996;208:93-5.

Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-61.

Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-50.

Lagrand WK, Hoogendoorn M, Bakker K, te Velde J, Labrie A. Aortoduodenal fistula as an unusual and fatal manifestation of giant-cell arteritis. Eur J Vasc Endovasc Surg 1996;11:502-3.

Lauwerys BR, Puttemans T, Houssiau FA, Devogelaer JP. Color Doppler sonography of the temporal arteries in giant cell arteritis and polymyalgia rheumatica. J Rheumatol 1997;24(8):1570-4.

Lee AG, Eggenberger ER, Kaufman DI, Manrique C. Optic nerve enhancement on magnetic resonance imaging in arteritic ischemic optic neuropathy. J Neuroophthalmol 1999;19:235-7.

Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990;33(8):1074-87.

Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995;24:422-31.

Liu KC, Chesnutt DA. Perineural optic nerve enhancement on magnetic resonance imaging in giant cell arteritis. J Neuroophthalmol 2013;33(3):279-81.

Liozon F, Jauberteau-Marchan MO, Boutros-Toni F, et al. Anticardiolipin antibodies and Horton disease. Ann Med Interne (Paris) 1995;146:541-7.

Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 2007;78(11):1255-9.

Loock J, Henes J, Kotter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012;30(1 Suppl 70):S70-6.

Machado E, Michet C, Ballard D, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 1988;31:745-9.

Mack HG, O'Day J, Currie JN. Delayed choroidal perfusion in giant cell arteritis. J Clin Neuroophthalmol 1991;11:221-7.

Marie I, Proux A, Duhaut P, et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine (Baltimore) 2009;88(3):182-92.

Martinez-Taboada VM, Goronzy JJ, Weyand CM. Clonally expanded CD8 T cells in patients with polymyalgia rheumatica and giant cell arteritis. Clin Immunol Immunopathol 1996;79:263-70.

Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67(5):625-30.

Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996;100:193-6.

Matzkin DC, Slamovits TL, Sachs R, Burde RM. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis. Ophthalmology 1992;99:68-71.

Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006;54(10):3310-8.

Meyer O, Nicaise P, Moreau S, et al. Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis. Rev Rhum Engl Ed 1996;63:241-7.

Morgenstern KE, Ellis BD, Schochet SS, Linberg JV. Bilateral optic nerve sheath enhancement from giant cell arteritis. J.Rheumatol 2003;30(3):625-7.

Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.

Murchison AP, Gilbert ME, Bilyk JR, et al. Validity of the American College of Rheumatology Criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol 2012 Jul 16. [Epub ahead or print].

Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 2002;29(10):2143-7.

Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992;31:103-5.

Nesher G, Gur H, Ehrenfeld M, Rubinow A, Sonnenblick M. The changing clinical presentation of temporal arteritis in Israel: a multicenter study. Isr Med Assoc J 1999;1(1):17-9.

Nesher G, Rubinow A, Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol 1997;15(3):303-6.

Nesher G, Shemesh D, Mates M, Sonnenblick M, Abramowitz HB. The predictive value of the halo sign in color Doppler ultrasonography of the temporal arteries for diagnosing giant cell arteritis. J Rheumatol 2002;29(6):1224-6.

Nordborg E, Nordborg C. The inflammatory reaction in giant cell arteritis: an immunohistochemical investigation. Clin Exp Rheumatol 1998;16:165-8.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003a;48(12):3522-31.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003b;48(12):3532-7.

Onuma K, Chu CT, Dabbs DJ. Asymptomatic giant-cell (temporal) arteritis involving the bilateral adnexa: case report and literature review. Int J Gynecol Pathol 2007;26(3):352-5.

Ostberg G. On arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand 1973;237:1-59.

Paulley JW, Hughes JP. Giant-cell arteritis, or arteritis of the aged. Br Med J 1960;2:1562-7.

Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999;38:1208-12.

Petursdottir V, Nordborg E, Nordborg C. Atrophy of the aortic media in giant cell arteritis. APMIS 1996;104:191-8.

Pipinos II, Hopp R, Edwards WD, Radio SJ. Giant-cell temporal arteritis in a 17-year-old male. J Vasc Surg 2006;43:1053-5.

Pountain GD, Calvin J, Hazleman BL. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994;33(6):550-4.

Prasad S, Baccon J, Galetta SL. Mydriatic pupil in giant cell arteritis. J Neurol Sci 2009;284(1-2):196-7.

Purvin V, Kawasaki A. Giant cell arteritis with spontaneous remission. Clin Experiment Ophthalmol 2007;35(1):59-61.

Quartuccio L, Maset M, De MG, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 2012;51(9):1677-86.

Rajesh CV, Cole M. Panuveitis as a presenting feature of giant cell arteritis [letter]. Br J Ophthalmol 2000;84:340.

Ray-Chaudhuri N, Kine DA, Tijani SO, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002;86(5):530-2.

Rozen TD. Brief Sharp Stabs of Head Pain and Giant Cell Arteritis. Headache 2010;50(9):1516-9.

Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 1999;58:303-8.

Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001;45(2):140-5.

Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002;137(4):232-8.

Sato M, Takeda A, Hagiwara S, et al. Giant cell arteritis and polymyalgia rheumatica presenting as subclavian artery obstruction. Ryumachi 1993;33:330-4.

Schallhorn J, Haug SJ, Yoon MK, Porco T, Seiff SR, McCulley TJ. A national survey of practice patterns: temporal artery biopsy. Ophthalmology 2013;120(9):1930-4.

Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005;17(1):9-15.

Sheehan MM, Keohane C, Twomey C. Fatal vertebral giant cell arteritis. J Clin Pathol 1993;46:1129-31.

Shick RM, Baggenstoss AH, Fuller BF, Polley HF. Effects of cortisone and ACTH on periarteritis nodosa and cranial arteritis. Mayo Clin Proc 1950;25:492-4.

Siatkowski RM, Gass JD, Glaser JS, Smith JL, Schatz NJ, Schiffman J. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 1993;115:57-63.

Siemonsen S, Brekenfeld C, Holst B, Kaufmann-Buehler AK, Fiehler J, Bley TA. 3T MRI reveals extra- and intracranial involvement in giant cell arteritis. AJNR Am J Neuroradiol 2014. [Epub ahead of print]

Slavin ML, Barondes MJ. Visual loss caused by choroidal ischemia preceding anterior ischemic optic neuropathy in giant cell arteritis. Am J Ophthalmol 1994;117:81-6.

Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum 1996;39:1747-53.

Tal S, Guller V, Gurevich A, Levi S. Fever of unknown origin in the elderly. J Intern Med 2002; 252(4):295-304.

Turlakow A, Yeung HW, Pui J, et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001;161(7):1003-7.

Valmaggia C, Speiser P, Bischoff P, Niederberger H. Indocyanine green versus fluorescein angiography in the differential diagnosis of arteritic and nonarteritic anterior ischemic optic neuropathy. Retina 1999;19:131-4.

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23.

Vecsei PV, Kircher K, Nagel G, Egger SF, Schneider B. Retrobulbar hemodynamics in amaurosis fugax; investigation by color Doppler velocity. Acta Ophthalmol Scand 1999;77:19-22.

Wagener HP, Hollenhorst RW. The ocular lesions of temporal arteritis. Am J Ophthalmol 1958;45:617-30.

Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43(5):1041-8.

Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349(2):160-9.

Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992;90:2355-61.

Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994;37:514-20.

Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002;46(2):457-66.

Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;40(1):19-26.

Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis: a pathologic study to show the pattern of involvement. Arch Neurol 1972;27:378-91.

Woods CA, editor. Memorandum book of a 10th century oculist. Chicago: Northwestern University, 1936.

Zenone T, Puget M. Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis. Rheumatol Int 2013. [Epub ahead of print]

**References especially recommended by the author or editor for general reading.

In This Article

Historical note and nomenclature
Clinical manifestations
Clinical vignette
Pathogenesis and pathophysiology
Differential diagnosis
Diagnostic workup
Prognosis and complications
References cited